Maravai Lifesciences Holdings (MRVI) EPS (Weighted Average and Diluted) (2020 - 2025)
Maravai Lifesciences Holdings has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$0.24 for Q4 2025.
- Quarterly results put EPS (Weighted Average and Diluted) at -$0.24 for Q4 2025, down 33.33% from a year ago — trailing twelve months through Dec 2025 was -$0.9 (up 11.76% YoY), and the annual figure for FY2025 was -$0.9, up 14.29%.
- EPS (Weighted Average and Diluted) for Q4 2025 was -$0.24 at Maravai Lifesciences Holdings, down from -$0.18 in the prior quarter.
- Over the last five years, EPS (Weighted Average and Diluted) for MRVI hit a ceiling of $0.53 in Q2 2022 and a floor of -$0.8 in Q4 2023.
- Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.05 (2023), compared with a mean of $0.02.
- Biggest five-year swings in EPS (Weighted Average and Diluted): soared 7647.81% in 2021 and later tumbled 1260.0% in 2024.
- Maravai Lifesciences Holdings' EPS (Weighted Average and Diluted) stood at $0.43 in 2021, then tumbled by 30.23% to $0.3 in 2022, then plummeted by 366.67% to -$0.8 in 2023, then soared by 77.5% to -$0.18 in 2024, then plummeted by 33.33% to -$0.24 in 2025.
- The last three reported values for EPS (Weighted Average and Diluted) were -$0.24 (Q4 2025), -$0.18 (Q3 2025), and -$0.27 (Q2 2025) per Business Quant data.